KENNETT SQUARE Although autumn is a month away, summertime is heating up in the borough for local residents. “Over the last few months, Borough Council has continued to hear concerns from residents regarding the status of the YMCA pool, specifically how the current availability, options and prices are not reflective of the spirit of […]
MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 359.66 ($4.56) and traded as low as GBX 296 ($3.75). MaxCyte shares last traded at GBX 302.50 ($3.84), with a volume of 77,582 shares […]
Operator: Thank you for standing by, and welcome to MaxCyte s Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.